CFDE Data Portal | Search KIAA2012-AS1

	Label	Description
	KIAA2012-AS1 Gene (Entity type)	ENSG00000222035 - KIAA2012 antisense RNA 1
	GSE226285 3 V 0 GLUTATHIONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE171177,GSE171181 1 V 0 E7107 HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE184902 4 V 0 ADIPONECTIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE56010 adenosine 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE154074 5 V 0 BLEOMYCIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE140441 temozolomide stem cell 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE185200 GSE185202 L-13 Ali-BL 0 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE115550 BRD4 inhibition 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE222676 ABCA1 knockout IMR-90 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

KIAA2012-AS1

ENSG00000222035 - KIAA2012 antisense RNA 1

GSE226285 3 V 0 GLUTATHIONE HUMAN UP

A Gene Set from LINCS

GSE171177,GSE171181 1 V 0 E7107 HUMAN UP

A Gene Set from LINCS

GSE184902 4 V 0 ADIPONECTIN MOUSE UP

A Gene Set from LINCS

GSE56010 adenosine 4 v 1 human dn

A Gene Set from LINCS

GSE154074 5 V 0 BLEOMYCIN MOUSE DN

A Gene Set from LINCS

GSE140441 temozolomide stem cell 2 v 0 human up

A Gene Set from LINCS

GSE185200 GSE185202 L-13 Ali-BL 0 v 9 human dn

A Gene Set from LINCS

GSE115550 BRD4 inhibition 2 v 1 human up

A Gene Set from LINCS

GSE222676 ABCA1 knockout IMR-90 1 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.